MediciNova, Inc. — Q3 2017 Form 10-Q Summary
Business context and reporting period
MediciNova is a clinical-stage biopharmaceutical company developing small-molecule therapeutics for serious diseases with unmet medical needs. Its principal programs are MN-166 (ibudilast) for neurological disorders and substance dependence, and MN-001 (tipelukast) for fibrotic diseases. The pipeline also includes MN-221 for acute asthma exacerbations and MN-029 for solid tumors. This unaudited report covers the three and nine months ended September 30, 2017.
Key financial metrics
| Metric | Three months ended September 30, 2017 | Nine months ended September 30, 2017 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $3.8 million | $9.6 million |
| Net loss | $3.8 million | $9.6 million |
| Net loss per share | $0.11 | $0.27 |
| Net cash used in operating activities | Not separately provided | $5.9 million |
| Cash and cash equivalents | $24.5 million at September 30, 2017 | |
| Working capital | $23.3 million at September 30, 2017 | |
| Total liabilities | $5.4 million at September 30, 2017 |
Research, development and patent expense was $1.3 million in the quarter and $3.1 million year to date. General and administrative expense was $2.5 million in the quarter and $6.6 million year to date. The filing does not present a meaningful operating margin because the company had no revenue. Stock-based compensation was $1.5 million in the quarter and $3.5 million year to date.
Financing activities provided $6.3 million during the first nine months, primarily from the sale of 1.1 million shares under the at-the-market program. The company had no debt reported as of September 30, 2017; liabilities consisted primarily of current liabilities, deferred tax liability and deferred revenue.
Material changes versus the prior comparable period
- Quarterly operating expenses increased 33% to $3.8 million from $2.8 million, driven by higher research and development activity and general and administrative expense.
- Quarterly net loss increased to $3.8 million from $2.8 million, and loss per share increased to $0.11 from $0.08.
- Year-to-date operating expenses increased 2% to $9.6 million from $9.4 million, while year-to-date net loss increased to $9.6 million from $9.4 million.
- Year-to-date operating cash use increased to $5.9 million from $5.5 million.
- Year-to-date financing proceeds declined to $6.3 million from $8.4 million. In 2016, financing was primarily from warrant and option exercises; in 2017, it was primarily from at-the-market equity sales.
- Cash increased modestly from $24.1 million at December 31, 2016 to $24.5 million at September 30, 2017.
- Shares outstanding increased to 35.7 million at September 30, 2017 from 34.5 million at December 31, 2016, reflecting equity issuance and exercises.
Guidance, outlook, risks and unusual items
Management expects substantial net losses to continue for the next several years as it advances its development programs. It stated that available working capital was expected to fund operations at least through December 31, 2019, but cautioned that it could not assure funding for all planned research and development programs.
Management expects research and development spending to increase as development programs progress. The company plans to advance MN-166 and MN-001 through company-funded, investigator-sponsored and grant-supported trials, and intends to seek strategic alliances to support later-stage development and commercialization.
- A shelf registration statement became effective on October 2, 2017, permitting offerings of up to $200 million of securities. Subsequent to quarter-end through October 20, 2017, the company generated $2.8 million in gross proceeds from additional at-the-market stock sales.
- The company and its joint venture partner agreed on July 24, 2017 to dissolve Zhejiang Sunmy, subject to Chinese regulatory approval. No sublicense of MN-221 had been entered into as of the filing date.
- The company had $1.7 million of long-term deferred revenue related to a Kissei research and development agreement; no related revenue was recognized during the reported periods.
- Outstanding warrants covered 869,047 shares and expire on May 9, 2018. Outstanding options covered 5.5 million shares as of September 30, 2017.
- Key risks include the need for additional capital, continued reliance on equity financing, clinical-trial delays or failures, regulatory approval risk, dependence on MN-166 and MN-001, third-party manufacturing and trial providers, intellectual-property disputes, competition and potential loss of key personnel.
- No material legal proceedings or material changes to previously disclosed risk factors were reported. Management concluded that disclosure controls were effective at the reasonable assurance level.
Important facts for investors to verify
- Whether the company can maintain its stated funding runway through December 31, 2019 while continuing planned clinical development.
- Progress, enrollment, results and funding sources for MN-166 trials in progressive MS, ALS and substance dependence.
- Clinical and regulatory progress for MN-001 in NASH and IPF.
- Terms, timing and dilution from additional at-the-market or shelf-registration offerings.
- Regulatory approval and expected accounting or economic consequences of dissolving Zhejiang Sunmy.
- The potential dilution from 5.5 million stock options and 869,047 warrants.
- Whether the company can generate partnership, licensing or product revenue, since no revenue was recognized in the reported periods.